SCHEMBL5966475

SCHEMBL5966475

COC(=O)CCCCCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.65
RXFP1 Q9HBX9 1/20 0.65
HDAC1 Q13547 4/20 0.62
ALOX5 P09917 2/20 0.62
HDAC2 Q92769 2/20 0.62
CES1 P23141 6/20 0.57
CA12 O43570 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
CA14 Q9ULX7 1/20 0.56
FAAH O00519 4/20 0.56
KDM4A O75164 1/20 0.54
KDM5A P29375 1/20 0.54
KDM4C Q9H3R0 1/20 0.54
PHF8 Q9UPP1 1/20 0.54
KDM2A Q9Y2K7 1/20 0.54
HDAC3 O15379 1/20 0.53
MAPK1 P28482 1/20 0.53
ADRA1A P35348 1/20 0.53
HDAC4 P56524 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9219599 1.00 MAPT (0.65) MAPTRXFP1HDAC1ALOX5HDAC2
SCHEMBL20717644 1.00 MAPT (0.65) MAPTRXFP1HDAC1ALOX5HDAC2
SCHEMBL29048467 1.00 MAPT (0.65) MAPTRXFP1HDAC1ALOX5HDAC2
SCHEMBL9404041 1.00 MAPT (0.65) MAPTRXFP1HDAC1ALOX5HDAC2
SCHEMBL8662111 1.00 MAPT (0.65) MAPTRXFP1HDAC1ALOX5HDAC2
SCHEMBL9764517 1.00 MAPT (0.65) MAPTRXFP1HDAC1ALOX5HDAC2
SCHEMBL9404082 1.00 MAPT (0.65) MAPTRXFP1HDAC1ALOX5HDAC2
SCHEMBL117432 0.98 MAPT (0.61) MAPTRXFP1HDAC1ALOX5HDAC2
Bromide SCHEMBL28931279 0.96 MAPT (0.59) MAPTRXFP1HDAC1ALOX5HDAC2
Water SCHEMBL27364393 0.96 MAPT (0.59) MAPTRXFP1HDAC1ALOX5HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867023-B2 Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material CANON KABUSHIKI KAISHA (JP) 2005-03-15 US claimed
US-20020081646-A1 Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material CANON KABUSHIKI KAISHA (JP) 2002-06-27 US claimed
EP-1201763-A2 Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material CANON KABUSHIKI KAISHA (JP) 2002-05-02 EP claimed
US-20200356000-A9 RADIATION-SENSITIVE COMPOSITION AND PATTERN-FORMING METHOD JSR CORPORATION (JP) 2020-11-12 US disclosed
US-20190354010-A1 RADIATION-SENSITIVE COMPOSITION AND PATTERN-FORMING METHOD JSR CORPORATION (JP) 2019-11-21 US disclosed
EP-2869389-B1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME MITSUBISHI CHEM CORP (JP) 2019-11-13 EP disclosed
US-10320030-B2 Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2019-06-11 US disclosed
CN-108473484-A Compounds useful as TRPM8 modulators 赛诺米克斯公司 2018-08-31 CN disclosed
US-9072293-B2 Cyclopropenes and method for applying cyclopropenes to agricultural products or crops ERUM BIOTECHNOLOGIES INC. (KR) 2015-07-07 US disclosed
US-20150140448-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2015-05-21 US disclosed
EP-2869389-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME Mitsubishi Chemical Corporation (JP) 2015-05-06 EP disclosed
EP-0275482-B1 PROLINE DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 1993-01-20 EP disclosed
US-5112847-A PROLINAL DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROLYL ENDOPEPTIDASE ONO PHARMACEUTICAL CO., LTD. (JP) 1992-05-12 US disclosed
US-5075447-A Biochemical immobilization; immunoassay HOFFMANN-LA ROCHE INC. (US) 1991-12-24 US disclosed
US-4983624-A Anemia ONO PHARMACEUTICAL CO., LTD (JP) 1991-01-08 US disclosed
CN-1009963-B RUTHENIUM COMPLEX BEING ABLE COUPLED WITH IMMUNO-ACTIVITY MATERIALS HOFFMANN LA ROCHE (CH) 1990-10-10 CN disclosed
EP-0275482-A2 Proline derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1988-07-27 EP disclosed
US-4745076-A Ruthenium complexes useful as carriers for immunologically active materials HOFFMANN-LA ROCHE INC. (US) 1988-05-17 US disclosed
CN-85107032-A The preparation of ruthenium complex and application 1987-04-01 CN disclosed
US-3931279-A 5-Oxa prostaglandin F2.sub.α analogs THE UPJOHN COMPANY (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020081646-A1 Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material FASN, FFAR1, ACADM MAPT 4818/4885RXFP1 1524/4885HDAC1 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.